Evaluation of Very High- and Very Low-Dose Intravitreal Aflibercept in Patients with Neovascular Age-Related Macular Degeneration

MLA

Alyson J. Berliner, et al. “Evaluation of Very High- and Very Low-Dose Intravitreal Aflibercept in Patients with Neovascular Age-Related Macular Degeneration.” Journal of Ocular Pharmacology and Therapeutics, vol. 28, Dec. 2012, pp. 581–88. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....87d953e1aa1d9b481678cc0ce083ebe5&authtype=sso&custid=ns315887.

APA

Alyson J. Berliner, Diana V. Do, Julia A. Haller, Peter K. Kaiser, Karen Chu, Peter A. Campochiaro, Henry L. Hudson, Jesse M. Cedarbaum, William F. Mieler, Robert Vitti, Avner Ingerman, Seenu M. Hariprasad, Peter L. Sonkin, Syed Mahmood Shah, Quan Dong Nguyen, David J. Browning, & Jason S. Slakter. (2012). Evaluation of Very High- and Very Low-Dose Intravitreal Aflibercept in Patients with Neovascular Age-Related Macular Degeneration. Journal of Ocular Pharmacology and Therapeutics, 28, 581–588.

Chicago

Alyson J. Berliner, Diana V. Do, Julia A. Haller, Peter K. Kaiser, Karen Chu, Peter A. Campochiaro, Henry L. Hudson, et al. 2012. “Evaluation of Very High- and Very Low-Dose Intravitreal Aflibercept in Patients with Neovascular Age-Related Macular Degeneration.” Journal of Ocular Pharmacology and Therapeutics 28 (December): 581–88. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....87d953e1aa1d9b481678cc0ce083ebe5&authtype=sso&custid=ns315887.